Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cytokinetics Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.8× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CYTK | |
|---|---|---|
Market Cap | $29.60B | $10.63B |
Sector | Health | Technology |
52-Week High | $491.22 | $87.26 |
52-Week Low | $205.48 | $34.31 |
Enterprise Value | $27.56B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
